Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19
File(s)1-s2.0-S0091674920312422-main.pdf (1.32 MB)
Published version
Author(s)
Type
Journal Article
Abstract
Background
Physicians treating COVID-19 patients increasingly believe that the hyperinflammatory acute stage of COVID-19 results in a cytokine storm. The circulating biomarkers seen across the spectrum of COVID-19 have not been characterized compared to healthy controls, but such analyses are likely to yield insights into the pursuit of interventions that adequately reduce the burden of these cytokine storms.
Objective
To identify and characterize the host inflammatory response to SARS-CoV-2 infection, we assessed levels of proteins related to immune responses and cardiovascular disease, in patients stratified as mild, moderate, and severe, versus matched healthy controls.
Methods
Blood samples from adult patients hospitalized with COVID-19 were analyzed using high-throughput and ultrasensitive proteomic platforms and compared with age- and sex-matched healthy controls to provide insights into differential regulation of 185 markers.
Results
Results indicate a dominant hyperinflammatory milieu in the circulation and vascular endothelial damage markers within COVID-19 patients, and strong biomarker association with patient response as measured by Ordinal scale. As patients progress, we observe statistically significant dysregulation of IFNγ, IL-1RA, IL-6, IL-10, IL-19, MCP-1, -2, -3, CXCL9, CXCL10, CXCL5, ENRAGE and PARP-1. Furthermore, in a limited series of patients who were sampled frequently confirming reliability and reproducibility of our assays, we demonstrate that intervention with baricitinib attenuates these circulating biomarkers associated with the cytokine storm.
Conclusion
These wide-ranging circulating biomarkers show an association with increased disease severity and may help stratify patients and selection of therapeutic options. They also provide insights into mechanisms of SARS-CoV-2 pathogenesis and the host response.
Physicians treating COVID-19 patients increasingly believe that the hyperinflammatory acute stage of COVID-19 results in a cytokine storm. The circulating biomarkers seen across the spectrum of COVID-19 have not been characterized compared to healthy controls, but such analyses are likely to yield insights into the pursuit of interventions that adequately reduce the burden of these cytokine storms.
Objective
To identify and characterize the host inflammatory response to SARS-CoV-2 infection, we assessed levels of proteins related to immune responses and cardiovascular disease, in patients stratified as mild, moderate, and severe, versus matched healthy controls.
Methods
Blood samples from adult patients hospitalized with COVID-19 were analyzed using high-throughput and ultrasensitive proteomic platforms and compared with age- and sex-matched healthy controls to provide insights into differential regulation of 185 markers.
Results
Results indicate a dominant hyperinflammatory milieu in the circulation and vascular endothelial damage markers within COVID-19 patients, and strong biomarker association with patient response as measured by Ordinal scale. As patients progress, we observe statistically significant dysregulation of IFNγ, IL-1RA, IL-6, IL-10, IL-19, MCP-1, -2, -3, CXCL9, CXCL10, CXCL5, ENRAGE and PARP-1. Furthermore, in a limited series of patients who were sampled frequently confirming reliability and reproducibility of our assays, we demonstrate that intervention with baricitinib attenuates these circulating biomarkers associated with the cytokine storm.
Conclusion
These wide-ranging circulating biomarkers show an association with increased disease severity and may help stratify patients and selection of therapeutic options. They also provide insights into mechanisms of SARS-CoV-2 pathogenesis and the host response.
Date Issued
2021-01
Date Acceptance
2020-08-12
Citation
Journal of Allergy and Clinical Immunology, 2021, 147 (1), pp.107-111
ISSN
0091-6749
Publisher
Elsevier
Start Page
107
End Page
111
Journal / Book Title
Journal of Allergy and Clinical Immunology
Volume
147
Issue
1
Copyright Statement
© 2020 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NCND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NCND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Sponsor
British Society for Antimicrobial Chemotherapy
Identifier
https://www.sciencedirect.com/science/article/pii/S0091674920312422?via%3Dihub
Grant Number
BSAC-COVID-32
Subjects
COVID-19
Ordinal Scale
baricitinib
biomarkers
cardiovascular
inflammation
Adult
Biomarkers
COVID-19
Cytokine Release Syndrome
Cytokines
Female
Humans
Male
Poly (ADP-Ribose) Polymerase-1
Proteomics
SARS-CoV-2
Humans
Cytokines
Proteomics
Adult
Female
Male
Biomarkers
Poly (ADP-Ribose) Polymerase-1
Cytokine Release Syndrome
COVID-19
SARS-CoV-2
Allergy
1107 Immunology
Publication Status
Published
Date Publish Online
2020-09-10